← boardnext 2026-12-31
GOVX
GeoVax, Inc.distress 6/10 · elevated risk$0.95+2%today-96% from 52w high
Lead: COVID-19 Infection
Revenue
pre-revenue
Liquidity
$1M
Runway
0.1 yrs
Shares 1y
-86%
Price & events
-66.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.8%
1D
+9.6%
1W
-26.1%
1M
-17.1%
3M
-69.7%
6M
-95.5%
1Y
-98.6%
2Y
-99.9%
5Y
-99.9%
All
Overview
- Market Cap
- $3.31M
- Volume
- 5.65K
- 52 Week Range
- $0.87 – $21.27
- Total Shares
- 3.47M
- Float Shares
- 3.20M
- Short %
- 1.21%
- % Held by Insiders
- 6.80%
- % Held by Institutions
- 18.28%
- RVOL
- 0.01x
- Beta
- 3.67
Pipeline stages · 1 programs
COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-31 Estimated 50% readout ~2027-02-14 | Phase 2 | COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1 | COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma | — | active not recruiting |
Catalyst news & presentations · 3
- 2025-03-25partnershipAmended August 2024 warrants to reduce exercise price to $1.31 and extend termination date to March 25, 2030.SEC 8-K
- 2025-03-25partnershipClosed registered direct offering of shares, pre-funded warrants, and common warrants for net proceeds of approximately $4.1 million.SEC 8-K
- 2024-10-15partnershipIncreased at-the-market offering capacity from $4,486,846 to $30,000,000SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-04-16D. Boral CapitalHold
- 2026-02-19D. Boral CapitalBuy → Hold
- 2026-01-21D. Boral CapitalBuy
- 2025-11-19D. Boral CapitalBuy
- 2025-09-26D. Boral CapitalBuy
- 2025-08-07D. Boral CapitalBuy
Competitors — COVID-19 Infection
- PFEPFIZER INC$142.2B · D3
Recent news
- 2026-07-21GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy - Yahoo Finance
- 2026-07-11GEOVAX LABS INC (GOVX) Stock Chart - ChartMill
- 2026-07-10GeoVax Labs Received Notice of Noncompliance - TradingView
- 2026-07-03GOVX Should I Buy - Intellectia AI
- 2026-06-25GOVX Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-22[Form 4] GeoVax Labs, Inc. Insider Trading Activity - Stock Titan
- 2026-06-22GeoVax (GOVX) director receives 6,000 stock options at $1.18 strike - Stock Titan
- 2026-06-22Director at GeoVax Labs (NASDAQ: GOVX) granted 6,000 options - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.